Bevacizumab (Avastin) is an antibody that targets vascular endothelial growth factor (VEGF). It may be effective against a number of solid tumors, but it is also associated with a number of serious toxicities, one of which is a hemolytic anemia.
Risk factors:
(1) combination therapy with paclitaxel/carboplatin
(2) combination therapy with sunitinib malate
Clinical features:
(1) hemolytic anemia with schistocytes
(2) thrombocytopenia
(3) variable renal dysfunction, hypertension and proteinuria secondary to glomerular thrombotic microangiopathy (podocytes produce VEGF)
